1. bookVolume 25 (2017): Issue 4 (October 2017)
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients

Published Online: 07 Nov 2017
Page range: 375 - 382
Received: 23 Mar 2017
Accepted: 04 Sep 2017
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Abstract

Introduction. The study of dialysis patients not needing erythropoiesis-stimulating agents (ESA) for long periods of time has gained interest lately. The aim of this study was to compare laboratory and clinical parameters in hemodialysis patients with autosomal dominant polycystic kidney disease (ADPKD) treated or not with ESA. Methods. Forty-six hemodialysis ADPKD patients were studied for 8 months and they were divided into: group 1- 29 patients who received ESA during the study period and group 2- 17 patients with no ESA treatment. The following parameters were determined: weekly treatment time, body mass index (BMI), pre-session diastolic blood pressure (DBP), pre-session systolic blood pressure (SBP), blood volume processed (BVD), interdialytic body weight gain (IBWG), spKt/V -K/DOQI formula (Kt/V), urea distribution volume (UDV), hemoglobin (Hb), ferritin, transferrin saturation (TSAT), serum phosphate, total serum calcium, normalized protein catabolic ratio (nPCR), albumin, and intact parathormone (PTH). Results. Patients not requiring ESA were more likely to be men, had higher Hb, albumin, total serum calcium levels, IBWG, UDV, BVP, and weekly treatment time. They had lower ferritin, TSAT, SBP. There was no difference regarding DBP, BMI, serum phosphate, PTH, Kt/V, and nPCR. Conclusion. Hemodialysis ADPKD patients not treated with ESA seem to be better nourished, with a slightly better SBP control, with longer dialysis time and increased Hb (despite lower iron loading markers), compared to hemodialysis ADPKD patients treated with ESA.

Keywords

1. Pop ND, Bacârea A, Coroș L, Aloiziu Dogaru G, Hosu I, Bacârea V, et al. Serum erythropoietin level in anemia of chronic kidney disease - experience of a Romanian medical center. Rev Romana Med Lab 2015;23(1):97-106. DOI: 10.1515/rrlm-2015-0003 10.1515/rrlm-2015-0003Open DOISearch in Google Scholar

2. Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, et al. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 2011 Feb;22(2):358-65. DOI: 10.1681/ASN.2010020173 10.1681/ASN.2010020173Open DOISearch in Google Scholar

3. Verdalles U, Abad S, Vega A, Ruiz Caro C, Ampuero J, Jofre R, et al. Factors related to the absence of anemia in hemodialysis patients. Blood Purif 2011;32(1):69-74. DOI: 10.1159/000323095 10.1159/000323095Open DOISearch in Google Scholar

4. Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004 Jul;44(1):94-111. DOI: 10.1053/j. ajkd.2004.03.023 10.1053/j.ajkd.2004.03.023Open DOISearch in Google Scholar

5. Eckardt KU, Mollmann M, Neumann R, Brunkhorst R, Burger HU, Lonnemann G, et al. Erythropoietin in polycystic kidneys. J Clin Invest 1989 Oct;84(4):1160-6. DOI: 10.1172/JCI114280 10.1172/JCI1142802794053Open DOISearch in Google Scholar

6. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006 Nov;355:2085-98. DOI: 10.1056/NEJMoa065485 10.1056/NEJMoa065485Open DOISearch in Google Scholar

7. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia.N Engl J Med 2006 Nov;355(20):2071-84. DOI: 10.1056/NEJMoa062276 10.1056/NEJMoa062276Open DOISearch in Google Scholar

8. Orasan OH, Orasan RA, Patiu MI, Dumitrascu DL. Hyaluronic acid in end-stage renal disease treated by hemodialysis. Renal failure 2015;37(9):1531-2. DOI: 10.3109/0886022X.2015.1077312 10.3109/0886022X.2015.1077312Open DOISearch in Google Scholar

9. Orasan OH, Sava M, Iancu M, Cozma A, Saplontai-Pop A, Sarlea Tarmure S, et al. Serum hyaluronic acid in chronic viral hepatitis B and C: a biomarker for assessing liver fibrosis in chronic hemodialysis patients. International Urology and Nephrology 2015 Jul;47(7), 1209-17. DOI: 10.1007/s11255-015-1017-x10.1007/s11255-015-1017-xOpen DOISearch in Google Scholar

10. Locatelli F, Altieri P, Andrulli S, Sau G, Bolasco P, Pedrini LA, et al. Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: results of a multicentre randomized and controlled trial. Nephrol Dial Transplant 2012 Sep;27(9):3594-600. DOI: 10.1093/ndt/gfs117 10.1093/ndt/gfs117Search in Google Scholar

11. Wan Q, He Y, Zhang W, Wu Q, Xiong Z. Prevalence and related factors of the absence of anemia among Chinese chronic hemodialysis patients: a multicenter cross-sectional study. Int Urol Nephrol 2014 Aug;46(8):1651-4. DOI: 10.1007/s11255-013-0581-1 10.1007/s11255-013-0581-1Search in Google Scholar

12. Takeda A, Toda T, Shinohara S, Mogi Y, Matsui N. Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin. Am J Kidney Dis 2002 Jul;40(1):104-9. DOI: 10.1053/ajkd.2002.33918 10.1053/ajkd.2002.33918Open DOISearch in Google Scholar

13. Murphy WG. The sex difference in haemoglobin levels in adults - mechanisms, causes, and consequences. Blood Rev 2014 Mar;28(2):41-7. DOI: 10.1016/j.blre.2013.12.003 10.1016/j.blre.2013.12.003Open DOISearch in Google Scholar

14. Shah A, Molnar MZ, Lukowsky LR, Zaritsky JJ, Kovesdy CP, Kalantar-Zadeh K. Hemoglobin level and survival in hemodialysis patients with polycystic kidney disease and the role of administered erythropoietin. Am J Hematol 2012 Aug;87(8):833-6. DOI: 10.1002/ajh.2325510.1002/ajh.23255Search in Google Scholar

15. Rahbari-Oskoui F, Williams O, Chapman A. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2014 Dec;29(12):2194-201. DOI: 10.1093/ndt/gft51310.1093/ndt/gft513Open DOISearch in Google Scholar

16. Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol 2009 Feb;4(2):470-80. DOI: 10.2215/CJN.05040908 10.2215/CJN.05040908Open DOISearch in Google Scholar

17. Orasan RA, Patiu IM, Anghel D, Bejan C, Iosub L, Totolici C, et al. Variation of clinical and laboratory features in chronic dialysis patients treated with high-flux hemodialysis after switching to online hemodiafiltration. Int Urol Nephrol 2013 Oct;45(5):1415-22. DOI: 10.1007/s11255-012-0341-710.1007/s11255-012-0341-7Open DOISearch in Google Scholar

18. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol 2006 Sep;1(Suppl 1):9-18.6 10.2215/CJN.01390406Search in Google Scholar

19. Gaweda AE, Bhat P, Maglinte GA, Chang CL, Hill J, Park GS, et al. TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients. Hemodial Int 2014 Jan;18(1):38-46. DOI: 10.1111/hdi.12078 10.1111/hdi.12078Open DOISearch in Google Scholar

20. Komaba H, Kakuta T, Fukagawa M. Management of secondary hyperparathyroidism: how and why? Clin Exp Nephrol 2017 Mar;21(Suppl 1):37-45. DOI: 10.1007/s10157-016-1369-2 10.1007/s10157-016-1369-2Open DOISearch in Google Scholar

21. Toida T, Iwakiri T, Sato Y, Komatsu H, Kitamura K, Fujimoto S. Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study. PLoS One 2017 Jan;12(1):e0169117. DOI: 10.1371/journal.pone.016911710.1371/journal.pone.0169117Search in Google Scholar

22. Artan AS, Kircelli F, Ok E, Yilmaz M, Asci G, Dogan C, et al. Dialyzing women and men: does it matter? An observational study. Clin Kidney J 2016 Jun;9(3):486-93. DOI: 10.1093/ckj/sfw013 10.1093/ckj/sfw013Open DOISearch in Google Scholar

23. Movilli E, Cancarini GC, Zani R, Camerini C, Sandrini M, Maiorca R. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant 2001 Jan;16(1):111-4. DOI: 10.1093/ndt/16.1.11110.1093/ndt/16.1.111Open DOISearch in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo